FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, February 22, 2025

Elon Musk vs. the 2000 Scientists: A Revolt Against Disruption or a Defense of Corruption?

Commentary by Richard Z. Cheng, M.D., Ph.D.

In what appears to be an unprecedented act of scientific rebellion, over 2000 scientists have co-authored an open letter urging the Royal Society to revoke Elon Musk's fellowship. Their justification? Musk's actions allegedly threaten scientific integrity and public trust in research institutions. But a deeper look suggests something far less noble-Musk is "moving their cheese", disrupting entrenched power structures, and exposing the corruption in what is supposed to be an objective, evidence-based field.

In February 2025, over 2,000 scientists co-authored an open letter urging the Royal Society to expel Elon Musk from its fellowship. The letter, initiated by Professor Stephen Curry of Imperial College London, criticizes Musk's recent public behavior and political affiliations, particularly his role as head of the U.S. Department of Government Efficiency (DOGE) under President Donald Trump. Signatories argue that Musk's actions undermine scientific research and contravene the Royal Society's code of conduct. In response, the Royal Society has scheduled a meeting on March 3 to discuss the matter, emphasizing that concerns about individual fellows are handled confidentially.

Musk's Real Crime: Challenging the Establishment

Elon Musk is no stranger to controversy, but the scientific community's reaction to him in recent years has been particularly revealing. Musk has:

1. Criticized the peer-review system, calling out its bias and manipulation by corporate and political interests.
2. Exposed the pharmaceutical-industrial complex, questioning vaccine mandates and the suppression of alternative treatments during the pandemic.
3. Disrupted academia's funding networks, as his vision for open-source research and AI threatens grant-dependent institutions that rely on corporate and government money.
4. Advocated for free speech, turning Twitter/X into a platform where dissenting scientific opinions (previously censored) can now be debated openly.

Each of these actions directly undermines the status quo, where research is often dictated by who funds it rather than what is true.

The Rotten Core of Institutional Science

The open letter against Musk isn't really about protecting science-it's about protecting the interests of those who control it. For decades, the so-called scientific establishment has been weaponized by corporate and political entities:

• Big Pharma funds medical research, ensuring outcomes that favor expensive, patentable drugs over natural or low-cost interventions.
• Climate science is dictated by government grants, rewarding alarmist narratives while silencing nuanced discussions.
• Peer review is a gatekeeping mechanism, allowing only politically and financially convenient research to be published.
• Dissenting scientists are blacklisted, their careers destroyed for challenging orthodoxy, whether on diet, vaccines, or energy policy.

Musk, by introducing decentralization, independent funding, and open discussion, threatens this system, which explains why these 2000 scientists are so desperate to discredit him.

A Sign of Desperation, Not Strength

This open letter is not a demonstration of power-it's a sign of fear. When establishment scientists need to collaborate en masse to denounce one man, it reveals that their authority is crumbling. The public is increasingly skeptical of corporate-controlled science, and Musk, despite his flaws, is accelerating that awakening.

The scientific revolution isn't coming from within the ivory towers, but from the outside-led by entrepreneurs, independent researchers, and free thinkers. And the establishment knows it.

By trying to cancel Musk, these 2000 scientists have only exposed their own irrelevance.

Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org

Find a Doctor

To locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

Editorial Review Board:

Jennifer L. Aliano, M.S., L.Ac., C.C.N. (USA)
Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)
Ilyès Baghli, M.D. (Algeria)
Greg Beattie, Author (Australia)
Barry Breger, M.D. (Canada)
Ian Brighthope, MBBS, FACNEM (Australia)
Gilbert Henri Crussol, D.M.D. (Spain)
Carolyn Dean, M.D., N.D. (USA)
Ian Dettman, Ph.D. (Australia)
Susan R. Downs, M.D., M.P.H. (USA)
Ron Ehrlich, B.D.S. (Australia)
Hugo Galindo, M.D. (Colombia)
Gary S. Goldman, Ph.D. (USA)
William B. Grant, Ph.D. (USA)
Claus Hancke, MD, FACAM (Denmark)
Patrick Holford, BSc (United Kingdom)
Ron Hunninghake, M.D. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Dwight Kalita, Ph.D. (USA)
Felix I. D. Konotey-Ahulu, M.D., FRCP (Ghana)
Peter H. Lauda, M.D. (Austria)
Fabrice Leu, N.D., (Switzerland)
Alan Lien, Ph.D. (Taiwan)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Pedro Gonzalez Lombana, M.D., Ph.D. (Colombia)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Juan Manuel Martinez, M.D. (Colombia)
Mignonne Mary, M.D. (USA)
Dr.Aarti Midha M.D., ABAARM (India)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Sarah Myhill, MB, BS (United Kingdom)
Tahar Naili, M.D. (Algeria)
Zhiyong Peng, M.D. (China)
Pawel Pludowski, M.D. (Poland)
Isabella Akyinbah Quakyi, Ph.D. (Ghana)
Selvam Rengasamy, MBBS, FRCOG (Malaysia)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Thomas N. Seyfried, Ph.D. (USA)
Han Ping Shi, M.D., Ph.D. (China)
T.E. Gabriel Stewart, M.B.B.CH. (Ireland)
Jagan Nathan Vamanan, M.D. (India)
Dr. Sunil Wimalawansa, M.D., Ph.D. (Sri Lanka)

Andrew W. Saul, Ph.D. (USA), Founding Editor
Richard Cheng, M.D., Ph.D. (USA), Editor-In-Chief
Associate Editor: Robert G. Smith, Ph.D. (USA)
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)
Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)
Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)
Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)
Editor, Spanish Edition: Sonia Rita Rial, PhD (Argentina)
Editor, German Edition: Bernhard Welker, M.D. (Germany)
Associate Editor, German Edition: Gerhard Dachtler, M.Eng. (Germany)
Assistant Editor: Michael Passwater (USA)
Contributing Editor: Thomas E. Levy, M.D., J.D. (USA)
Contributing Editor: Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)
Contributing Editor: W. Todd Penberthy, Ph.D. (USA)
Contributing Editor: Ken Walker, M.D. (Canada)
Contributing Editor: Michael J. Gonzalez, N.M.D., Ph.D. (Puerto Rico)
Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)
Associate Technology Editor: Robert C. Kennedy, M.S. (USA)
Legal Consultant: Jason M. Saul, JD (USA)

Comments and media contact: editor@orthomolecular.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

To Subscribe at no charge: http://www.orthomolecular.org/subscribe.html

To Unsubscribe from this list: http://www.orthomolecular.org/unsubscribe.html